FDA announced approval of daraxonrasib, a new targeted treatment for pancreatic cancer. CU Anschutz physician Dr. Wells Messersmith served as principal investigator.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Daraxonrasib approved by FDA: Pancreatic cancer drug shown to improve survival
minute read
by 9News | August 31, 2026
